Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 84 FCF Margin % is 10.93% as of Dec. 2025, which is 6% above its 10-year median of 10.32. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 963 Drug Manufacturers companies, TSH Biopharm ranks better than 69.89% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TSH Biopharm's Free Cash Flow for the
three
months ended in Dec. 2025 was NT$39 Mil. TSH Biopharm's Revenue for the
three
months ended in Dec. 2025 was NT$358 Mil. Therefore, TSH Biopharm's FCF Margin % for the quarter that ended in Dec. 2025 was 10.93%.
The historical rank and industry rank for TSH Biopharm's FCF Margin % or its related term are showing as below:
ROCO:8432'
s FCF Margin % Range Over the Past 10 Years
Min: 2.06 Med: 10.32 Max: 16.84
Current: 9.66
During the past 13 years, the highest FCF Margin % of TSH Biopharm was 16.84%. The lowest was 2.06%. And the median was 10.32%.
ROCO:8432's FCF Margin % is ranked better than 69.89% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs ROCO:8432: 9.66
TSH Biopharm FCF Margin % Related Terms
TSH Biopharm FCF Margin % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's FCF Margin % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a FCF Margin % of 10.93% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TSH Biopharm and its competitors. This is near median its historical median of 10.32. Over the past decade, TSH Biopharm's FCF Margin % has ranged from 2.06 to 16.84. According to the industry distribution chart, TSH Biopharm ranks #290 out of 963 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is TSH Biopharm's FCF Margin % too high?
TSH Biopharm's current FCF Margin % of 10.93% is near median its 10-year median of 10.32. Over the past 10 years, this metric has ranged from a low of 2.06 to a high of 16.84. The Drug Manufacturers industry median FCF Margin % is 2.57. TSH Biopharm's value of 10.93% is 325.3% above this industry median. Based on the distribution chart, TSH Biopharm ranks #290 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #290 out of 963 companies for FCF Margin %. This puts TSH Biopharm in the upper half of its industry. The industry median FCF Margin % is 2.57. TSH Biopharm's value of 10.93% is 325.3% above this benchmark. Historically, TSH Biopharm's own FCF Margin % has ranged from 2.06 to 16.84 over the past decade. While the company's 10-year median is 10.32 vs. the industry median of 2.57, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current FCF Margin % of 10.93% is 325.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current FCF Margin % is 10.93%, which is near median its own 10-year median of 10.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current FCF Margin % is 10.93%, which is near median its 10-year median of 10.32 and 325.3% above the Drug Manufacturers industry median of 2.57. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current FCF Margin % is 10.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
FCF Margin %: 10.93% (near median its 10-year median of 10.32)
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
Industry Position: 325.3% above the Drug Manufacturers median (#290 of 963)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
